Prognostic value of hormone receptors in breast cancer

✍ Scribed by Tadaoki Morimoto; Kansei Komaki; Hiroyuki Yamamoto; Takashi Yamakawa; Takashi Tanaka; Hiroshi Sonoo; Yasumasa Monden

• Publisher: John Wiley and Sons
• Year: 1988
• Tongue: English
• Weight: 432 KB
• Volume: 39
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930390207

✦ Synopsis

The aim of this study was to establish the role of estrogen receptor (ER) and progesterone receptor (PgR) as prognostic indicators for early recurrence and survival. In all, among breast cancer patients, 166 patients who had undergone radical or extended radical mastectomy were studied. These patients were treated with adjuvant chemotherapy alone for 2-3 years after surgery. No patients had adjuvant endocrine therapy. Local recurrence and/or distant metastases were treated by endocrine therapy and/or chemotherapy. The relapse-free interval was not different between the ER-positive and ER-negative patients. The postrelapse survival curve was significantly different between the two groups. There was no significant difference in the relapse-free interval and the postrelapse survival curve between the PgR-positive and PgR-negative patients. These results suggest that ER is a good predictor of the response to endocrine therapy given after relapse, but not of early recurrence.